Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Carcinoma, Neuroendocrine 1

Interventions

fludarabine phosphate 18Cyclophosphamide 16Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 11Busulfan 11Tacrolimus 10Mycophenolic Acid 10ruxolitinib 9fludarabine 7Methotrexate 6Cyclosporine 6Radiotherapy 5Aspirin 5Prednisone 4Melphalan 4Imatinib Mesylate 4Biopsy 4Antilymphocyte Serum 4peginterferon alfa-2a 3givinostat hydrochloride 3givinostat 3Stem Cell Transplantation 3Specimen Handling 3Decitabine 3bomedemstat 2Thiotepa 2Surveys and Questionnaires 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methylprednisolone 2Lenalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Polycythemia Vera × iadademstat × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡